Compare · BHG vs NTRA
BHG vs NTRA
Side-by-side comparison of Bright Health Group Inc. (BHG) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BHG and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $58.35B, about 34.9x BHG ($1.67B).
- NTRA has hit the wire 10 times in the past 4 weeks while BHG has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Bright Health Group Inc.
- Natera Inc.
- Price
- -
- -
- Market cap
- $1.67B
- $58.35B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2015
- News (4w)
- 0
- 10
- Recent ratings
- 25
- 25
Bright Health Group Inc.
Bright Health Group, Inc., an integrated care delivery company, engages in the delivery and financing of health insurance plans in the United States. It operates in two segments, NeueHealth and Bright HealthCare. The company offers individual and family, Medicare, and employers insurance plans. It also operates 28 managed and affiliated risk-bearing primary care clinics. The company was formerly known as Bright Health Inc. and changed its name to Bright Health Group, Inc. in February 2021. Bright Health Group, Inc. was incorporated in 2015 and is based in Minneapolis, Minnesota.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest BHG
- SEC Form SC 13G/A filed by Bright Health Group Inc. (Amendment)
- SEC Form SC 13D/A filed by Bright Health Group Inc. (Amendment)
- Bright Health Group Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Bright Health Group Adopts NeueHealth As Corporate Brand Name; Company's Common Stock Will Begin Trading Under The New Ticker Symbol "NEUE" On The New York Stock Exchange, Effective January 29, 2024
- Bright Health Group Adopts NeueHealth as Corporate Brand Name
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Bright Health Group Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Bright Health Group Closes Sale Of Its California Medicare Advantage Business To Molina Healthcare, Reaffirms Expectation For Adj. EBITDA Profitability In 2024
- Bright Health Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
Latest NTRA
- SEC Form 4 filed by Natera Inc.
- Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
- SEC Form 4 filed by Natera Inc.
- FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
- Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
- New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
- Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $1,242,645 worth of shares (3,000 units at $414.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 106,914 units (SEC Form 4)
- CEO AND PRESIDENT Chapman Steven Leonard sold $526,144 worth of shares (1,273 units at $413.31) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 96,926 units (SEC Form 4)